Human telomerase reverse transcriptase mRNA expression assessed by real-time reverse transcription polymerase chain reaction predicts chemosensitivity in patients with ovarian carcinoma

Fiamma Buttitta, Caterina Pellegrini, Antonio Marchetti, Angiolo Gadducci, Stefania Cosio, Lara Felicioni, Fabio Barassi, Simona Salvatore, Carla Martella, Guido Coggi, Silvano Bosari

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Purpose: To evaluate in vivo whether the expression of the human telomerase reverse transcriptase (hTERT) gene, the catalytic subunit of the telomerase complex, is predictive of response to chemotherapy in ovarian cancer patients. Patients and Methods: Fifty-nine advanced-stage ovarian cancer patients who were treated with platinum-based chemotherapy were studied. hTERT levels were evaluated by real-time reverse transcriptase polymerase chain reaction (RT-PCR) on tumor specimens obtained before the treatment. Variables were analyzed by the χ2 and Fisher's exact tests. Logistic regression analysis was also performed to account for the effects of all the covariates investigated (residual disease, stage, histotype, and grade). Results: Twenty-eight (47%) of the 59 tumors showed low hTERT levels, whereas 31 (53%) tumors displayed high hTERT levels. Seventy-five percent of complete responders showed high levels of hTERT expression, whereas 66% of partial responders or nonresponders exhibited low HTERT levels (P = .002). Only residual disease and hTERT expression were independent predictors of response (odds ratios, 13.455 and 7.586, respectively). The combination of these two parameters provides powerful predictive information: 18 of the 20 patients with residual disease more than 2 cm and low hTERT levels were partial responders or nonresponders, whereas 11 of the 12 patients with residual disease less than 2 cm and high hTERT levels showed a complete response (χ2 = 21,416; P <.00001). Conclusion: Our data indicate that hTERT expression, measured by real-time RT-PCR, is a possible independent marker of response to platinum-based therapy in advanced stage ovarian cancer patients. Prospective validation of this marker will be required to further define its predictive value.

Original languageEnglish
Pages (from-to)1320-1325
Number of pages6
JournalJournal of Clinical Oncology
Volume21
Issue number7
DOIs
Publication statusPublished - Apr 1 2003

Fingerprint

Reverse Transcription
Carcinoma
Polymerase Chain Reaction
Messenger RNA
Ovarian Neoplasms
Telomerase
Platinum
Reverse Transcriptase Polymerase Chain Reaction
Real-Time Polymerase Chain Reaction
human TERT protein
Drug Therapy
Neoplasms
Logistic Models
Odds Ratio
Regression Analysis
Therapeutics
Genes

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Human telomerase reverse transcriptase mRNA expression assessed by real-time reverse transcription polymerase chain reaction predicts chemosensitivity in patients with ovarian carcinoma. / Buttitta, Fiamma; Pellegrini, Caterina; Marchetti, Antonio; Gadducci, Angiolo; Cosio, Stefania; Felicioni, Lara; Barassi, Fabio; Salvatore, Simona; Martella, Carla; Coggi, Guido; Bosari, Silvano.

In: Journal of Clinical Oncology, Vol. 21, No. 7, 01.04.2003, p. 1320-1325.

Research output: Contribution to journalArticle

Buttitta, Fiamma ; Pellegrini, Caterina ; Marchetti, Antonio ; Gadducci, Angiolo ; Cosio, Stefania ; Felicioni, Lara ; Barassi, Fabio ; Salvatore, Simona ; Martella, Carla ; Coggi, Guido ; Bosari, Silvano. / Human telomerase reverse transcriptase mRNA expression assessed by real-time reverse transcription polymerase chain reaction predicts chemosensitivity in patients with ovarian carcinoma. In: Journal of Clinical Oncology. 2003 ; Vol. 21, No. 7. pp. 1320-1325.
@article{fe8cbd63406c4a03a61c65c6f3bd8444,
title = "Human telomerase reverse transcriptase mRNA expression assessed by real-time reverse transcription polymerase chain reaction predicts chemosensitivity in patients with ovarian carcinoma",
abstract = "Purpose: To evaluate in vivo whether the expression of the human telomerase reverse transcriptase (hTERT) gene, the catalytic subunit of the telomerase complex, is predictive of response to chemotherapy in ovarian cancer patients. Patients and Methods: Fifty-nine advanced-stage ovarian cancer patients who were treated with platinum-based chemotherapy were studied. hTERT levels were evaluated by real-time reverse transcriptase polymerase chain reaction (RT-PCR) on tumor specimens obtained before the treatment. Variables were analyzed by the χ2 and Fisher's exact tests. Logistic regression analysis was also performed to account for the effects of all the covariates investigated (residual disease, stage, histotype, and grade). Results: Twenty-eight (47{\%}) of the 59 tumors showed low hTERT levels, whereas 31 (53{\%}) tumors displayed high hTERT levels. Seventy-five percent of complete responders showed high levels of hTERT expression, whereas 66{\%} of partial responders or nonresponders exhibited low HTERT levels (P = .002). Only residual disease and hTERT expression were independent predictors of response (odds ratios, 13.455 and 7.586, respectively). The combination of these two parameters provides powerful predictive information: 18 of the 20 patients with residual disease more than 2 cm and low hTERT levels were partial responders or nonresponders, whereas 11 of the 12 patients with residual disease less than 2 cm and high hTERT levels showed a complete response (χ2 = 21,416; P <.00001). Conclusion: Our data indicate that hTERT expression, measured by real-time RT-PCR, is a possible independent marker of response to platinum-based therapy in advanced stage ovarian cancer patients. Prospective validation of this marker will be required to further define its predictive value.",
author = "Fiamma Buttitta and Caterina Pellegrini and Antonio Marchetti and Angiolo Gadducci and Stefania Cosio and Lara Felicioni and Fabio Barassi and Simona Salvatore and Carla Martella and Guido Coggi and Silvano Bosari",
year = "2003",
month = "4",
day = "1",
doi = "10.1200/JCO.2003.09.065",
language = "English",
volume = "21",
pages = "1320--1325",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "7",

}

TY - JOUR

T1 - Human telomerase reverse transcriptase mRNA expression assessed by real-time reverse transcription polymerase chain reaction predicts chemosensitivity in patients with ovarian carcinoma

AU - Buttitta, Fiamma

AU - Pellegrini, Caterina

AU - Marchetti, Antonio

AU - Gadducci, Angiolo

AU - Cosio, Stefania

AU - Felicioni, Lara

AU - Barassi, Fabio

AU - Salvatore, Simona

AU - Martella, Carla

AU - Coggi, Guido

AU - Bosari, Silvano

PY - 2003/4/1

Y1 - 2003/4/1

N2 - Purpose: To evaluate in vivo whether the expression of the human telomerase reverse transcriptase (hTERT) gene, the catalytic subunit of the telomerase complex, is predictive of response to chemotherapy in ovarian cancer patients. Patients and Methods: Fifty-nine advanced-stage ovarian cancer patients who were treated with platinum-based chemotherapy were studied. hTERT levels were evaluated by real-time reverse transcriptase polymerase chain reaction (RT-PCR) on tumor specimens obtained before the treatment. Variables were analyzed by the χ2 and Fisher's exact tests. Logistic regression analysis was also performed to account for the effects of all the covariates investigated (residual disease, stage, histotype, and grade). Results: Twenty-eight (47%) of the 59 tumors showed low hTERT levels, whereas 31 (53%) tumors displayed high hTERT levels. Seventy-five percent of complete responders showed high levels of hTERT expression, whereas 66% of partial responders or nonresponders exhibited low HTERT levels (P = .002). Only residual disease and hTERT expression were independent predictors of response (odds ratios, 13.455 and 7.586, respectively). The combination of these two parameters provides powerful predictive information: 18 of the 20 patients with residual disease more than 2 cm and low hTERT levels were partial responders or nonresponders, whereas 11 of the 12 patients with residual disease less than 2 cm and high hTERT levels showed a complete response (χ2 = 21,416; P <.00001). Conclusion: Our data indicate that hTERT expression, measured by real-time RT-PCR, is a possible independent marker of response to platinum-based therapy in advanced stage ovarian cancer patients. Prospective validation of this marker will be required to further define its predictive value.

AB - Purpose: To evaluate in vivo whether the expression of the human telomerase reverse transcriptase (hTERT) gene, the catalytic subunit of the telomerase complex, is predictive of response to chemotherapy in ovarian cancer patients. Patients and Methods: Fifty-nine advanced-stage ovarian cancer patients who were treated with platinum-based chemotherapy were studied. hTERT levels were evaluated by real-time reverse transcriptase polymerase chain reaction (RT-PCR) on tumor specimens obtained before the treatment. Variables were analyzed by the χ2 and Fisher's exact tests. Logistic regression analysis was also performed to account for the effects of all the covariates investigated (residual disease, stage, histotype, and grade). Results: Twenty-eight (47%) of the 59 tumors showed low hTERT levels, whereas 31 (53%) tumors displayed high hTERT levels. Seventy-five percent of complete responders showed high levels of hTERT expression, whereas 66% of partial responders or nonresponders exhibited low HTERT levels (P = .002). Only residual disease and hTERT expression were independent predictors of response (odds ratios, 13.455 and 7.586, respectively). The combination of these two parameters provides powerful predictive information: 18 of the 20 patients with residual disease more than 2 cm and low hTERT levels were partial responders or nonresponders, whereas 11 of the 12 patients with residual disease less than 2 cm and high hTERT levels showed a complete response (χ2 = 21,416; P <.00001). Conclusion: Our data indicate that hTERT expression, measured by real-time RT-PCR, is a possible independent marker of response to platinum-based therapy in advanced stage ovarian cancer patients. Prospective validation of this marker will be required to further define its predictive value.

UR - http://www.scopus.com/inward/record.url?scp=0037837653&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037837653&partnerID=8YFLogxK

U2 - 10.1200/JCO.2003.09.065

DO - 10.1200/JCO.2003.09.065

M3 - Article

VL - 21

SP - 1320

EP - 1325

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 7

ER -